Username Password
S&P 500: 1,351.68 Change: +0.14%

ONCOTHYREON (ONTY)

Overview
Price 8.01
Price Change Today -$0.21 (-2.55%)
P&P rating Rating: 5
Zacks Rank 3 - HOLD
Open Price $8.23
Previous Close $8.22
Daily Range $7.88 - $8.25
52-Week Range $3.01 - $11.59
Volume 676,138
chart
Oncothyreon Inc., formerly Biomira Inc. is a clinical-stage biopharmaceutical company focused primarily on the development and commercialization of therapeutic products for the treatment of cancer. The company is currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Headquartered in Seattle, Washington, the primary goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. The Company's lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer. Oncothyreon has an exclusive, worldwide collaboration agreement with Merck KGaA of Darmstadt, Germany, for the development and commercialization of Stimuvax. Its pipeline of clinical and preclinical-stage small molecule product candidates includes PX-12, PX-478 and PX-866, from ProlX Pharmaceuticals Corporation.
Other Resources for ONTY
zacks.com
Commentary
Zacks Blog: Merck KGaA Washes Hands of PD Drug
October 24, 2011
Zacks Blog: Merck KGaA, Ono Pharma Collaborate
October 14, 2011
Oncothyreon Inc., formerly Biomira Inc. is a clinical-stage biopharmaceutical company focused primarily on the development and commercialization of therapeutic products for the treatment of cancer. The company is currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Headquartered in Seattle, Washington, the primary goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. The Company's lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer. Oncothyreon has an exclusive, worldwide collaboration agreement with Merck KGaA of Darmstadt, Germany, for the development and commercialization of Stimuvax. Its pipeline of clinical and preclinical-stage small molecule product candidates includes PX-12, PX-478 and PX-866, from ProlX Pharmaceuticals Corporation.
 
Brokerage Analyst Recommendations
5 Brokerage Firms Covering ONTY
 
 
Strong Buy
5
Buy
0
Hold
0
Sell
0
Strong Sell
0
Average Broker Recommendation (ABR): 1
 
ONTY Ratings:BUY  SELL  HOLD
ONTY Consensus Forecasts
Rate this Stock!
You haven't rated this stock yet!

What The Community Thinks

Total Players

15 Buy
0 Sell
 
Top Buy Analysis
BUY: ONTY Rating: 5
Company: ONCOTHYREON INC . - COMMON SHARES
Points: 1.74
Start Price: $7.54
Start Date: 10/29/2011 5:30 PM
Turkish_Master
Turkish_Master
P&P Score: 99.35
Recs:
Poisitive Analyst Institution

Comments: 0 | Comment


Top Sell Analysis
No Sell Analysis. Be the First.
Blog Posts
User User Score Date Title Comments Last Comment
Zacks_Analysts
0.00 10/24/11 Merck KGaA Washes Hands off PD Drug - Analyst Blog 0
Commentary
BUY: ONCOTHYREON INC . - COMMON SHARES (ONTY) Rating: 5
Start Price: $7.54
Points: +1.74
Created: 10/29/2011
Poisitive Analyst Institution

Comments: 0 | Comment

Recs:
 
BUY: ONCOTHYREON INC . - COMMON SHARES (ONTY) Rating: 5
Start Price: $5.39
Points: +28.25
Created: 01/03/2010
Merck's actions showing strong confidence in Stimuvax efficacy.

Comments: 0 | Comment

Recs:
 
BUY: ONCOTHYREON INC . - COMMON SHARES (ONTY) Rating: 5
Start Price: $5.39
Points: +28.25
Created: 12/31/2009
5 star

Comments: 0 | Comment

Recs:
 
BUY: ONCOTHYREON INC . - COMMON SHARES (ONTY) Rating: 5
Start Price: $6.93
Points: +2.48
Created: 11/22/2011
tsyg

Comments: 0 | Comment

Recs:
 
BUY: ONCOTHYREON INC . - COMMON SHARES (ONTY) Rating: 5
Start Price: $4.09
Points: +71.78
Created: 10/24/2009

Comments: 0 | Comment

Recs:
 
BUY: ONCOTHYREON INC . - COMMON SHARES (ONTY) Rating: 5
Start Price: $3.00
Points: +176.47
Created: 01/01/2008

Comments: 0 | Comment

Recs:
 
BUY: ONCOTHYREON INC . - COMMON SHARES (ONTY) Rating: 5
Start Price: $3.00
Points: +176.47
Created: 01/01/2008

Comments: 0 | Comment

Recs:
 
BUY: ONCOTHYREON INC . - COMMON SHARES (ONTY) Rating: 5
Start Price: $3.00
Points: +176.47
Created: 01/01/2008

Comments: 0 | Comment

Recs:
 
BUY: ONCOTHYREON INC . - COMMON SHARES (ONTY) Rating: 5
Start Price: $3.00
Points: +176.47
Created: 01/01/2008

Comments: 0 | Comment

Recs:
 
BUY: ONCOTHYREON INC . - COMMON SHARES (ONTY) Rating: 5
Start Price: $3.00
Points: +176.47
Created: 01/01/2008

Comments: 0 | Comment

Recs:
 
Pages: [ 1 ]  2  >>
Picks
Username P&P Score Call Time Frame Start Date Start Price Today (change) Stock Gain S&P Gain Points Analysis
Yade 99.88 BUY One to Three Years 11/22/2011 $6.93 $8.06
(-1.63%)
+16.25% +13.77% +2.48 view
Turkish_Master 99.35 BUY Week to a Month 10/29/2011 $7.54 $8.06
(-1.63%)
+6.92% +5.18% +1.74 view
TraitorHook BUY Three to Six Months 01/03/2010 $5.39 $8.06
(-1.63%)
+49.47% +21.22% +28.25 view
wneili 4.27 BUY Week or Less 12/31/2009 $5.39 $8.06
(-1.63%)
+49.47% +21.22% +28.25 view
poconobear 95.08 BUY Six Months to a Year 10/24/2009 $4.09 $8.06
(-1.63%)
+96.98% +25.20% +71.78
maximus 59.97 BUY Six Months to a Year 01/01/2008 $3.00 $8.06
(-1.63%)
+168.55% -7.92% +176.47
IrwinK 83.02 BUY Six Months to a Year 01/01/2008 $3.00 $8.06
(-1.63%)
+168.55% -7.92% +176.47
Bull152ar 21.39 BUY Six Months to a Year 01/01/2008 $3.00 $8.06
(-1.63%)
+168.55% -7.92% +176.47
trader269 11.73 BUY Six Months to a Year 01/01/2008 $3.00 $8.06
(-1.63%)
+168.55% -7.92% +176.47
Frankthetank242 27.37 BUY Six Months to a Year 01/01/2008 $3.00 $8.06
(-1.63%)
+168.55% -7.92% +176.47
Pages: [ 1 ]  2  >>
Sponsored Links